이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성, 전이성 또는 난치성 비인두암에서 표적 약물 카보잔티닙을 사용하거나 사용하지 않는 니볼루맙 및 이필리무맙 면역요법 테스트

2026년 10월 30일 업데이트: National Cancer Institute (NCI)

백금 치료 및 면역요법 후에 진행된 진행성 비인두 암종 환자에서 카보잔티닙을 포함하거나 포함하지 않는 니볼루맙 및 이필리무맙의 무작위 2상 연구

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]).

SECONDARY OBJECTIVES:

I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.).

II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.

III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.

EXPLORATORY OBJECTIVE:

I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.

ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.

After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years.

연구 유형

중재적

등록 (추정된)

50

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Irvine, California, 미국, 92612
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Los Angeles, California, 미국, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90020
        • Keck Medicine of USC Koreatown
      • Los Angeles, California, 미국, 90033
        • Los Angeles General Medical Center
      • Newport Beach, California, 미국, 92663
        • USC Norris Oncology/Hematology-Newport Beach
      • Orange, California, 미국, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Palo Alto, California, 미국, 94304
        • Stanford Cancer Institute Palo Alto
    • Georgia
      • Atlanta, Georgia, 미국, 30308
        • Emory University Hospital Midtown
    • Idaho
      • Boise, Idaho, 미국, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, 미국, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, 미국, 83814
        • Kootenai Health - Coeur d'Alene
      • Nampa, Idaho, 미국, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, 미국, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, 미국, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, 미국, 60612
        • University of Illinois
      • Danville, Illinois, 미국, 61832
        • Carle at The Riverfront
      • DeKalb, Illinois, 미국, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Effingham, Illinois, 미국, 62401
        • Carle Physician Group-Effingham
      • Evanston, Illinois, 미국, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Geneva, Illinois, 미국, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, 미국, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Glenview, Illinois, 미국, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, 미국, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Harvey, Illinois, 미국, 60426
        • Ingalls Memorial Hospital
      • Highland Park, Illinois, 미국, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Lake Forest, Illinois, 미국, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Mattoon, Illinois, 미국, 61938
        • Carle Physician Group-Mattoon/Charleston
      • New Lenox, Illinois, 미국, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • Orland Park, Illinois, 미국, 60462
        • University of Chicago Medicine-Orland Park
      • Orland Park, Illinois, 미국, 60462
        • Northwestern Medicine Orland Park
      • Urbana, Illinois, 미국, 61801
        • Carle Cancer Center
      • Warrenville, Illinois, 미국, 60555
        • Northwestern Medicine Cancer Center Warrenville
    • Iowa
      • Ankeny, Iowa, 미국, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Clive, Iowa, 미국, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, 미국, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Council Bluffs, Iowa, 미국, 51503
        • Heartland Oncology and Hematology LLP
      • Council Bluffs, Iowa, 미국, 51503
        • Methodist Jennie Edmundson Hospital
      • Council Bluffs, Iowa, 미국, 51503
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
      • Des Moines, Iowa, 미국, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, 미국, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, 미국, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, 미국, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Waukee, Iowa, 미국, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
    • Massachusetts
      • Boston, Massachusetts, 미국, 02111
        • Tufts Medical Center
    • Minnesota
      • Bemidji, Minnesota, 미국, 56601
        • Sanford Joe Lueken Cancer Center
    • Missouri
      • St Louis, Missouri, 미국, 63128
        • Mercy Hospital South
    • Montana
      • Anaconda, Montana, 미국, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, 미국, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, 미국, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, 미국, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, 미국, 59901
        • Logan Health Medical Center
      • Missoula, Montana, 미국, 59804
        • Community Medical Center
    • Nebraska
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, 미국, 68114
        • Oncology Associates PC
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, 미국, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, 미국, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, 미국, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, 미국, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale, New York, 미국, 11553
        • Memorial Sloan Kettering Nassau
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, 미국, 28204
        • Novant Health Presbyterian Medical Center
      • Huntersville, North Carolina, 미국, 28078
        • Novant Health Cancer Institute - Huntersville
      • Matthews, North Carolina, 미국, 28105
        • Novant Health Cancer Institute - Matthews
      • Mooresville, North Carolina, 미국, 28117
        • Novant Health Cancer Institute - Mooresville
    • North Dakota
      • Bismarck, North Dakota, 미국, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, 미국, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Cincinnati, Ohio, 미국, 45220
        • Good Samaritan Hospital - Cincinnati
    • Oklahoma
      • Lawton, Oklahoma, 미국, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, 미국, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, 미국, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Ontario, Oregon, 미국, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, 미국, 97239
        • Oregon Health and Science University
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • Medical University of South Carolina
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, 미국, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Nashville, Tennessee, 미국, 37232
        • Vanderbilt University/Ingram Cancer Center
    • Virginia
      • Richmond, Virginia, 미국, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, 미국, 23298
        • VCU Massey Comprehensive Cancer Center
    • West Virginia
      • Morgantown, West Virginia, 미국, 26506
        • West Virginia University Healthcare
      • Parkersburg, West Virginia, 미국, 26101
        • Camden Clark Medical Center
    • Wisconsin
      • Eau Claire, Wisconsin, 미국, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Marshfield, Wisconsin, 미국, 54449
        • Marshfield Medical Center-Marshfield
      • Minocqua, Wisconsin, 미국, 54548
        • Marshfield Medical Center - Minocqua
      • Rice Lake, Wisconsin, 미국, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, 미국, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Weston, Wisconsin, 미국, 54476
        • Marshfield Medical Center - Weston

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must have histologically documented nasopharyngeal carcinoma (NPC) regardless of World Health Organization (WHO) classification (keratinizing squamous cell carcinoma, non-keratinizing, or basaloid squamous cell carcinoma) and regardless of association with Epstein-Barr virus (EBV) and/or human papillomavirus (HPV)

  • Recurrent, metastatic and incurable disease treated with platinum-gemcitabine and prior PD-1/L1 blockade (as first or second-line therapy)

  • Patients are eligible regardless of prior smoking history, p16 immunohistochemistry (IHC) status, PD-L1 expression status, EBV tumor status, EBV viral load at baseline, or tumor genomic alteration status

  • Patients must have at least one measurable lesion (by RECIST v1.1) which has not been previously irradiated that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions as >= 10 mm (>= 1 cm) (and short axis for nodal lesions, LN >= 15 mm) with CT scan, MRI, or calipers by clinical exam

  • Patients may have had no more than 2 prior lines of prior systemic therapy for recurrent, metastatic NPC

  • No prior VEGFR targeted therapy permitted

  • Age >= 18 years

  • Eastern Cooperative Oncology Group Performance (ECOG) performance status 0-2

  • Absolute neutrophil count (ANC) >= 1,000/mm^3

  • Hemoglobin >= 9 g/dL

  • Platelet count >= 100,000/mm^3

  • Creatinine or creatinine clearance =< 1.5 mg/dL or >= 30 Modification of Diet in Renal Disease (MDRD)

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGT]) =< 3 x upper limit of normal (ULN)

    • Up to =< 5 allowed with liver metastases
  • Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test, per institution standard, done =< 7 days prior to registration is required.

    • Pregnant women are excluded from this study because nivolumab, ipilimumab, and cabozantinib are all Class C or D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with any of the study agents, breastfeeding should be discontinued if the mother is treated with as part of this study (in either arm)
  • No active tumor bleeding: or radiographic evidence of major blood vessel infiltration as judged by the treating investigator

  • Prior -anti-cancer therapy is allowed: Patients need to be recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia. Any life-threatening events clearly attributable to prior immunotherapy exposure that have a high possibility of recurring should warrant exclusion: including severe pneumonitis, grade 4 bullous dermatitis/drug reaction with eosinophilia and systemic symptoms (DRESS), neurologic events such as autoimmune encephalitis transverse myelitis, and/or myocarditis. Maintenance hormonal replacement or long-term hormonal therapy exposure is permitted.

    • No chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:

      • Repeat imaging demonstrates no new sites of bone metastases.
      • The lesion being considered for palliative radiation is not a target lesion
  • No patients with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen

  • Brain metastases allowed: Patients with treated brain metastases are eligible if follow-up brain imaging 3 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial

  • For patients with evidence of chronic hepatitis B (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently receiving treatment, they are eligible if they have an undetectable HCV viral load
  • Solid organ or tissue transplant is allowed: - subsequent therapy with nivolumab increases the risk of organ/tissue rejection. Patients must be instructed that it is crucial they stay in touch with their transplant team during treatment

  • No active autoimmune disease: or history of autoimmune disease that might recur, and which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of

    • Immune related neurologic disease,
    • Multiple sclerosis,
    • Autoimmune (demyelinating) neuropathy,
    • Guillain-Barre syndrome (GBS),
    • Myasthenia gravis;
    • Systemic autoimmune disease such as SLE,
    • Connective tissue diseases,
    • Scleroderma, inflammatory bowel disease (IBD),
    • Crohn's, ulcerative colitis,
    • Patients with a history of toxic epidermal necrolysis (TEN),
    • Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
  • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible

  • Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome, and psoriasis controlled with topical medication and patients with only positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

  • Pneumonitis should be evaluated for the nature of the disease process, need for treatment prior study treatment, and the risk of exacerbation with study treatment

  • Able to swallow oral medication: No known medical condition causing an inability to swallow oral formulations of agents

  • No condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study registration. Patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted

  • Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel) is prohibited. Allowed anticoagulants are the following:

    • Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
    • Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
  • Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A4 is discouraged; if unavoidable, the dose of cabozantinib on study should be adjusted accordingly. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study are prohibited

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Arm A (nivolumab, ipilimumab)

Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial.

Given IV

다른 이름들:
  • 항세포독성 T-림프구 관련 항원-4 단클론항체
  • BMS-734016
  • 이필리무맙 바이오시밀러 CS1002
  • MDX-010
  • MDX-CTLA4
  • 여보이
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given IV

다른 이름들:
  • BMS-936558
  • MDX-1106
  • 니보
  • ONO-4538
  • 옵디보
  • CMAB819
  • 니볼루맙 바이오시밀러 CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • 니볼루맙 바이오시밀러 ABP 206
  • BCD-263
  • 니볼루맙 바이오시밀러 BCD-263
  • BMS936558
  • 오노 4538
  • ONO4538

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT scan

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형
실험적: Arm B (nivolumab, ipilimumab, cabozantinib)

Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.

Given IV

다른 이름들:
  • 항세포독성 T-림프구 관련 항원-4 단클론항체
  • BMS-734016
  • 이필리무맙 바이오시밀러 CS1002
  • MDX-010
  • MDX-CTLA4
  • 여보이
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • BMS-907351
  • 카보메틱스
  • 코메트릭
  • XL-184
  • XL184
  • 특대형 184

Given IV

다른 이름들:
  • BMS-936558
  • MDX-1106
  • 니보
  • ONO-4538
  • 옵디보
  • CMAB819
  • 니볼루맙 바이오시밀러 CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • 니볼루맙 바이오시밀러 ABP 206
  • BCD-263
  • 니볼루맙 바이오시밀러 BCD-263
  • BMS936558
  • 오노 4538
  • ONO4538

Undergo collection of blood samples

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT scan

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS)
기간: From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years

PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.

From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Overall survival (OS)
기간: From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years

OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms.

From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
Incidence of adverse events
기간: Up to 2 years

The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the chi-square or Fisher's exact test.

Up to 2 years
Response by subgroups of interest
기간: Up to 2 years

Will also report and compare the overall response rate (ORR) between different subgroups of interest (primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy (further defined below), etc.). These comparisons will be done via chi-square or Fisher's exact tests. We'll also assess primary versus acquired resistance to prior PD-1 inhibition in each arm as well. While not a formal stratification, in the interim and final analysis we'll also descriptively assess these subgroups between arms as well.

Up to 2 years
ORR
기간: Up to 2 years

The response rate will be compared via chi-square or Fisher's exact tests between the 2 treatment arms using both the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and also separately for the immune-modified RECIST criteria.

Up to 2 years
Predictors of response
기간: Up to 2 years

Will correlate the baseline data (Epstein-Barr virus viral load, p16 immunohistochemistry status, smoking history, and PD-L1 score) with ORR data. For this analysis, logistic regression models will be assessed using the baseline data to predict binary response data. Odds ratios and 95% confidence intervals will be reported. Will also summarize the data using descriptive statistics and graphical methods.

Up to 2 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Ari J Rosenberg, Alliance for Clinical Trials in Oncology

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 19일

기본 완료 (추정된)

2028년 12월 6일

연구 완료 (추정된)

2028년 12월 6일

연구 등록 날짜

최초 제출

2023년 6월 13일

QC 기준을 충족하는 최초 제출

2023년 6월 13일

처음 게시됨 (실제)

2023년 6월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 30일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다